TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8913184
Drug: Medical antireflux
Normalized name: VALVE,ANTIREFLUX UROCARE #6001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical antireflux therapy (ranitidine plus cisapride)
Study: 1991415
Drug: 7.5 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 percent semisolid gel
Study: 6856646
Drug: Procaine (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine (48 mg, 96 mg)
Study: 29578090
Drug: Adjunctive internet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive internet cognitive‐behavioral therapy
Study: 29578090
Drug: Adjunctive internet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive internet education
Study: 27488327
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (300,000 IU intramuscular)
Study: 27488327
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (1 mL as placebo)
Study: 23791016
Drug: Structured withdrawal
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured withdrawal program (60 mcg/day for 15 days and then 60 mcg every second evening for another 15 days)
Study: 24308282
Drug: Tailored intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tailored intervention including training on medication management, provision of evidence-based checklists, a tablet PC with an interactive educational tool, and information leaflets for patients.
Study: 18832497
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (second-generation antidepressants)
Study: 16877896
Drug: Conventional antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antipsychotics (haloperidol 10 or 20 mg/day, perphenazine mean dose 28 mg/day, zuclopenthixol mean dose 38 mg/day)
Study: 12512025
Drug: EP-1 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: EP-1 antagonist ZD6416
Study: 3864167
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) infusion therapy (100 micrograms/day, 3-hour intravenous infusion for three weeks)
Study: 30430724
Drug: Single 2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2-g oral dose of TXA 2 h preoperatively followed by 1 g of oral TXA 3 h postoperatively (group B)
Study: 30430724
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose followed by 1 g of oral TXA 3 h and 7 h postoperatively (group C)
Study: 30430724
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose followed by 1 g of oral TXA 3 h, 7 h and 11 h postoperatively (group D)
Study: 30430724
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose followed by 1 g of oral TXA 3 h, 7 h, 11 h and 15 h postoperatively (group E)
Study: 22833405
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow-derived mononucleated cells (BM-MNC)
Study: 18541126
Drug: NSPN extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSPN extract (360 mg Nigella sativa and 50 mg Phyllanthus niruri), administered 3 times daily for 7 days
Study: 10937982
Drug: Candoxatril 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril 200 mg b.d. (n = 22)
Study: 10937982
Drug: Captopril 25-50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25-50 mg b.d. (n = 23)
Study: 3315295
Drug: Transcutaneous cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous cardiac pacing (PACE) in addition to standard advanced cardiac life support (ACLS) treatment
Study: 16714186
Drug: Adjuvanted 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted 30 microg formulation
Study: 11343051
Drug: Vinblastine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine (6 mg/m², given intravenously every week)
Study: 11343051
Drug: Etoposide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (150 mg/m²/d, given intravenously for 3 days every 3 weeks)
Study: 7664216
Drug: lisinopril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril (ACE inhibitor)
Study: 7664216
Drug: losartan (Ang
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan (Ang II receptor antagonist)
Study: 7664216
Drug: hydrochlorothiazide (thiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide (thiazide diuretic)
Study: 2570004
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg terfenadine three times daily
Study: 1071694
Drug: Chlorothiazide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorothiazide (0.5 g twice daily)
Study: 1071694
Drug: Metolazone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metolazone (5 mg daily)
Study: 23971894
Drug: Prescription opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription opioid misuse
Study: 23465653
Drug: Metoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (5 mg IV over 5 min on commencement of bypass then 5 mg IV qid for 24h then 25-50 mg tds orally until discharge)
Study: 23465653
Drug: Combined metoprolol
Normalized name: metoprolol and thiazides, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined metoprolol and amiodarone (300 mg over 1h starting shortly after the commencement of bypass, then 900 mg over 24h then 400 mg orally tds until discharge)
Study: 18813410
Drug: Injection plus
Normalized name: Bimectin Plus Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection plus physiotherapy
Study: 18813410
Drug: Brace injection
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace injection
Study: 16368830
Drug: Epidural neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural neostigmine infusion (500 microg bolus before anesthesia induction, followed by 125 microg/h until end of surgery)
Study: 16368830
Drug: Epidural neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural neostigmine infusion (500 microg bolus at end of surgery)
Study: 16368830
Drug: Epidural neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural neostigmine infusion (500 microg bolus before anesthesia induction)
Study: 14561539
Drug: Implanon (etonogestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implanon (etonogestrel 68 mg, single‐rod)
Study: 14561539
Drug: Norplant (levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norplant (levonorgestrel 36 mg, six capsules)
Study: 2310661
Drug: Intravenous nisoldipine
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nisoldipine
Study: 380737
Drug: Povidone-iodine spray
Normalized name: povidone-iodine Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone-iodine spray
Study: 31418516
Drug: Add-on insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on insulin therapy
Study: 29078817
Drug: High-dose pitavastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pitavastatin (4 mg)
Study: 25377166
Drug: Oral route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral route (trainees)
Study: 25377166
Drug: Oral route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral route (experts)
Study: 17257177
Drug: Gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200 mg (Group II, n = 25)
Study: 17257177
Drug: Gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200 mg and 20 mg/kg paracetamol (Group III, n = 25)
Study: 17257177
Drug: Gabapentin (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (Group II) and Gabapentin + Paracetamol (Group III)
Study: 17257177
Drug: Gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200 mg (Group II) and Gabapentin + Paracetamol (Group III)
Study: 11961238
Drug: G-CSF (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (1 microg/kg IV)
Study: 11961238
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 microg/kg IV)
Study: 11961238
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg/kg twice daily)
Study: 21040545
Drug: Directly-observed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly-observed therapy (DOT)
Study: 9098476
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of cyproterone acetate and 20 mg of ethynyl‐estradiol in an inversal sequential scheme for six months
Study: 2478788
Drug: UD‐CG 115
Approvals — FDA: no, EMA: no, PMDA: no
Description: UD‐CG 115 BS 5 mg p.o.
Study: 2478788
Drug: UD‐CG 115
Approvals — FDA: no, EMA: no, PMDA: no
Description: UD‐CG 115 BS 10 mg p.o.
Study: 2478788
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with 10 mg of UD‐CG 115 BS/day over 5 days
Study: 2478788
Drug: Dobutamine (optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (optimal dose)
Study: 6993122
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment followed by delayed operation (n=30)
Study: 31680331
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g fibrinogen concentrate
Study: 28228426
Drug: Probiotic (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2) 2 capsules/d, 1.5 billion colony-forming units/capsule for 8 weeks
Study: 22464209
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of embryo culture supernatant before embryo transfer
Study: 19924786
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment of both primary tumor and metastases
Study: 19924786
Drug: Any local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any local treatment of either primary tumor or metastases
Study: 19924786
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of local treatment
Study: 12184365
Drug: Subcutaneous (s.q.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.q.) administration of AVA
Study: 8534466
Drug: 70% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70% N2O in 30% O2 administered by face mask for 120 seconds
Study: 8534466
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g of EMLA cream under an occlusive dressing for a minimum of 60 minutes
Study: 2178535
Drug: Ranitidine, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 300 mg orally, administered 1 hour before running
Study: 2178535
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered after a low-fat breakfast before baseline pH recording
Study: 17533210
Drug: Complex clinical
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex clinical models (including 2-hour post-OGTT glucose, fasting insulin, C-reactive protein, Gutt insulin sensitivity index, homeostasis model insulin resistance)
Study: 15570070
Drug: Marimastat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marimastat (10 mg bid)
Study: 15570070
Drug: Marimastat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marimastat (10 mg bid) with plasma concentration ≥ 10 ng/mL
Study: 9458569
Drug: Oral presentation
Normalized name: Gas-X Prevention Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral presentation about infant immunization
Study: 8169430
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses after two injections
Study: 28438182
Drug: Forced fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced fluid removal with a therapeutic target of negative net fluid balance ≥1 mL/kg/h
Study: 22560371
Drug: D-cycloserine (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (50mg once weekly)
Study: 17701037
Drug: Gemcitabine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 400 mg/m2 (dose level 0)
Study: 17701037
Drug: Gemcitabine 200
Normalized name: gemcitabine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 200 mg/m2 (dose level -1)
Study: 17701037
Drug: Hematologic toxicity
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hematologic toxicity at dose level 0
Study: 12613268
Drug: Esberitox N
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esberitox N (herbal immunomodulator), dosage: 3 x 2 tablets daily, duration: from 3 days prior to injection to 2 weeks after injection
Study: 12613268
Drug: Placebo, dosage:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, dosage: 3 x 2 tablets daily, duration: from 3 days prior to injection to 2 weeks after injection
Study: 11910665
Drug: CEE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE therapy (0.625 mg/day of conjugated equine estrogen)
Study: 11910665
Drug: CEE/MPA therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE/MPA therapy (0.625 mg/day of CEE and 2.5 mg/day of medroxyprogesterone acetate)
Study: 8730943
Drug: Antidepressants and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants and behavioural counselling
Study: 1924235
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 10% isoniazid solution
Study: 1924235
Drug: Oral isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isoniazid
Study: 22294737
Drug: n-3 LCPUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 LCPUFA supplementation (fish oil capsules providing 900 mg of n-3 LCPUFA daily)
Study: 22294737
Drug: Control (matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (matched vegetable oil capsules without n-3 LCPUFA)
Study: 18802718
Drug: Buffered isotonic
Normalized name: ISOTON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered isotonic saline solution
Study: 16551896
Drug: 5-day opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day opioid weaning using oral methadone
Study: 16551896
Drug: 10-day opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day opioid weaning using oral methadone
Study: 12923131
Drug: Methotrexate and
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate and Mifepristone (600 mg given orally)
Study: 12923131
Drug: Methotrexate and
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate and Mifepristone (600 mg given orally) with progesterone level >/=10 ng/l
Study: 12923131
Drug: Methotrexate and
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate and Placebo with progesterone level >/=10 ng/l
Study: 8775573
Drug: Pre-exercise glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-exercise glycerol hydration (1.2 gm/kg glycerol in 26 ml/kg solution)
Study: 8775573
Drug: Pre-exercise placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-exercise placebo hydration (26 ml/kg of aspartame flavored water)
Study: 25005331
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein pre-load (50 g whey in 250 ml water)
Study: 25005331
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 ml water)
Study: 22887019
Drug: HQK-1001 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HQK-1001 at 10 or 20 mg/kg doses
Study: 22887019
Drug: HQK-1001 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HQK-1001 at 30 mg/kg/day
Study: 16133954
Drug: Loperamide 2
Normalized name: loperamide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 2 mg/day
Study: 16133954
Drug: Loperamide 4
Normalized name: loperamide 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 4 mg/day
Study: 16133954
Drug: Loperamide 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 6 mg/day
Study: 11896377
Drug: Light exercise
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light exercise therapy
Study: 10396858
Drug: I-131 therapy
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-131 therapy
Study: 10396858
Drug: I-131 therapy
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-131 therapy + external beam radiotherapy (RT)
Study: 1974505
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg once daily for 4 weeks
Study: 1974505
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg once daily + HCTZ 25 mg once daily for 10 weeks
Study: 1974505
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg once daily + HCTZ 25 mg once daily for 10 weeks
Study: 6116461
Drug: Alfentanil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (0.5 mg/ml)
Study: 6116461
Drug: Fentanyl (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.05 mg/ml)
Study: 31097414
Drug: Stepped-care intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care intervention (eight sessions of individual problem-solving therapy, with an extra two to four sessions if needed) plus enhanced usual care
Study: 17101741
Drug: NXY-059 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXY-059 (15 mg/mL) during 12 hours
Study: 12800796
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy and radiation
Study: 12800796
Drug: Intraperitoneal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal treatment
Study: 11155057
Drug: Remifentanil hydrochloride,
Normalized name: Remifentanil Hydrochloride, 1 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil hydrochloride, bolus doses of 1 microgram/kg followed by continuous infusions of 0.1‐0.5 microgram/kg/min, titrated to effect.
Study: 9124202
Drug: G‐CSF (arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (arm A)
Study: 9124202
Drug: G‐CSF followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF followed by GM‐CSF (arm B)
Study: 29095347
Drug: Reference oral
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reference oral liquid formula (Neocate) (group 2)
Study: 26373657
Drug: Longitudinal care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longitudinal care (telephone-based counseling and nicotine replacement therapy for 12 months)
Study: 26373657
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (standard 8-week treatment)
Study: 22464164
Drug: HES 130/0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 130/0.4 preload (500 mL)
Study: 22464164
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution preload (1000 mL)
Study: 16117771
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) instilled locally before implant placement
Study: 12324668
Drug: Daily rhDNase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rhDNase (2.5 mg once daily)
Study: 12324668
Drug: Alternate day
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate day rhDNase (2.5 mg every other day)
Study: 12324668
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (5 ml 7% HS twice daily)
Study: 12080402
Drug: Walnut diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut diet (12.5% of energy from walnuts, 44-58 g/day)
Study: 9733272
Drug: Cyclophosphamide (CP)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CP) at a dose of 50 mg/kg daily infused intravenously over 1 hour for 4 days (in aplastic anemia patients)
Study: 9733272
Drug: Cyclophosphamide (CP)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CP) at a dose of 60 mg/kg by i.v. infusion over 1 hour daily for 2 days followed by total body irradiation (in leukemia patients)
Study: 8296403
Drug: Intermittent suction
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent suction and pressure (Vacusac treatment)
Study: 28202500
Drug: Walking intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Walking intervention comprising Macmillan's 'Move More' information, a short motivational interview recommending to walk for at least 30 minutes on alternate days and attend a volunteer-led group walk weekly.
Study: 18675597
Drug: Endometrial aspiration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial aspiration before saline infusion sonography (SIS)
Study: 18675597
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion sonography (SIS) before endometrial aspiration
Study: 12867217
Drug: Aprepitant 375
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 375 mg PO, dexamethasone 20 mg PO, ondansetron 32 mg IV on day 1, followed by aprepitant 250 mg PO and dexamethasone 8 mg PO on days 2 through 5